Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

61.43
+2.924.99%
Post-market: 61.430.00000.00%19:30 EST
Volume:3.07M
Turnover:186.48M
Market Cap:11.87B
PE:-620.04
High:61.70
Open:58.50
Low:58.28
Close:58.51
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:1.64
T/O Rate:1.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0991
EPS(LYR):1.80
ROE:-0.31%
ROA:3.89%
PB:1.90
PE(LYR):34.13

Loading ...

Biomarin Pharmaceutical Inc. : Canaccord Genuity Raises Target Price to $117 from $114

THOMSON REUTERS
·
10 hours ago

H.C. Wainwright Sticks to Its Hold Rating for BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Nov 17

S&P 500 Futures Fall in Premarket Trading; TELUS Corp., Vaxcyte Lead

Dow Jones
·
Nov 16

How A $1 Billion Quarter At BioMarin Pharmaceutical (BMRN) Has Changed Its Investment Story

Simply Wall St.
·
Nov 14

BioMarin Pharmaceutical (BMRN) Receives a Buy from Evercore ISI

TIPRANKS
·
Nov 14

BioMarin Pharmaceutical Price Target Cut to $103.00/Share from $119.00 by Morgan Stanley

Dow Jones
·
Nov 14

B. Riley Adjusts BioMarin Pharmaceutical Price Target to $27 From $34, Maintains Buy Rating

MT Newswires Live
·
Nov 13

US Research Roundup-Azenta, Cencora, Stratasys

Reuters
·
Nov 13

BioMarin Updates Vosoritide Study in Rare Growth Disorder

TIPRANKS
·
Nov 13

How Investors Are Reacting To BioMarin (BMRN) Lowered Revenue Guidance

Simply Wall St.
·
Nov 07

Scynexis Names Sanjay Subramanian Chief Financial Officer

Reuters
·
Nov 05

BioMarin to Present at Stifel, UBS and Jefferies Investor Conferences

Reuters
·
Nov 04

Netherlands' uniQure Q3 Revenue Misses Estimates

Reuters
·
Nov 04

Movement Alert|Biomarin Pharmaceutical Pre-Market Rise 5.17%, Wedbush Says Revenue Base Can Support New Growth Opportunities

Market Focus
·
Nov 04

US Research Roundup-Amgen, Carmax, Pfizer

Reuters
·
Nov 04

Barclays Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Nov 04

Zevra Therapeutics Q3 Revenue Rises 45% on Miplyffa Sales

Reuters
·
Nov 04

BioMarin Pharmaceutical Price Target Maintained with a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
Nov 04

BioMarin Likely Able to Support New Prospects, Wedbush Says

MT Newswires Live
·
Nov 04

Movement Alert|Biomarin Pharmaceutical Falls 5.62% in Regular Trading, Full-Year Adjusted EPS Guidance Cut Well Below Expectations

Market Focus
·
Nov 04